- Piramal Pharma rose 13.63% to ₹225.81 at 10:09 IST on 28 Oct 2026.
- Volume so far was 14.63× its 20-session average.
- Q2 FY27 net profit: ₹5 crore.
- Nifty Pharma was +0.27%.
Figures as of: 10:09 IST, Wednesday 28 October 2026
Piramal Pharma Ltd. share price rose 13.63% to ₹225.81 at 10:09 IST on Wednesday 28 October 2026. The company filed its Q2 FY27 results on Tuesday 27 October 2026, and the stock traded higher on Wednesday morning. Trading volume reached 14.63× the 20-session average. The company reported a net profit of ₹5 crore for the quarter.
Piramal Pharma share price today
| Price (10:09 IST) | ₹225.81 |
| Change from the previous close (₹198.72) | +₹27.09 (+13.63%) |
| Day’s range | ₹209.04 – ₹225.90 |
| Volume so far | 3.40 crore shares |
| 20-session average daily volume | 23.2 lakh shares (volume so far is 14.63× that) |
| Closing prices of the previous 4 sessions | ₹191.07 – ₹198.72 |
| 52-week range (adjusted prices) | ₹132.30 – ₹231.93 |
| Price against that range | 2.6% below the high, 70.7% above the low |
| Market value at this price | ₹30,063 crore |
The stock traded between ₹209.04 and ₹225.90 during the morning session. Volume reached 3.40 crore shares, which is 14.63× the 20-session average daily volume. The current price of ₹225.81 is 2.6% below the 52-week high of ₹231.93.
What has been announced
| When (IST) | Filing |
|---|---|
| Tue 27 Oct, 9:06 pm | Announcement under Regulation 30 (LODR)-Investor Presentation |
| Tue 27 Oct, 9:04 pm | Announcement under Regulation 30 (LODR)-Press Release / Media Release |
| Tue 27 Oct, 8:59 pm | Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended September 30 2026 |
| Tue 27 Oct, 8:53 pm | Board Meeting Outcome for Outcome Of Board Meeting Of Piramal Pharma Limited Held On 27Th October 2026 |
Q2 FY27 results at a glance
| ₹ crore | Q2 FY27 | Q2 FY26 | Change | Q1 FY27 | Change |
|---|---|---|---|---|---|
| Revenue from operations | 2,617 | 2,044 | +28.05% | 2,270 | +15.29% |
| Profit before tax | 82 | −46 | – | −7 | – |
| Net profit | 5 | −99 | – | −69 | – |
| Net profit as a share of revenue | 0.19% | −4.85% | – | −3.06% | – |
Piramal Pharma reported Q2 FY27 revenue from operations of ₹2,617 crore, which is 28.05% higher than a year earlier. The company recorded a profit before tax of ₹82 crore for the quarter. Net profit for the period was ₹5 crore, compared to a net outflow of ₹64 crore for the first six months of the fiscal year.
How Piramal Pharma compares with its sector
| Change today | |
|---|---|
| Piramal Pharma | +13.63% |
| Nifty Pharma | +0.27% |
| Nifty 50 | −0.85% |
| Torrent Pharmaceuticals | −2.22% |
| Glenmark Pharmaceuticals | +1.54% |
| Ipca Laboratories | −1.50% |
| Laurus Labs | +1.46% |
The Nifty Pharma index gained 0.3% while the Nifty 50 was −0.85%. Among peers, Glenmark Pharmaceuticals rose 1.54% and Laurus Labs gained 1.46%. Torrent Pharmaceuticals was −2.22% and Ipca Laboratories was −1.50%.
Piramal Pharma share price: FAQs
What is the Piramal Pharma share price today?
₹225.81 at 10:09 IST on Wednesday 28 October 2026, up ₹27.09 or 13.63% from the previous close of ₹198.72.
What were Piramal Pharma’s Q2 FY27 results?
Consolidated revenue from operations of ₹2,617 crore (+28.05% year on year) and net profit of ₹5 crore, for the quarter ended 30 September 2026.
When did Piramal Pharma announce the results?
The board meeting outcome was filed on Tue 27 Oct, 8:59 pm IST.
How is the Pharma sector doing today?
Nifty Pharma was +0.27% at 10:09 IST on Wednesday 28 October 2026, against +13.63% for Piramal Pharma.
This article is for information only and is not investment advice. Prices are from the National Stock Exchange, filings from BSE announcements and results from the company’s reported figures. Calculations are by ThePip. Prices and figures move through the session; the time above says when these were read. Investments in securities are subject to market risks.